RecruitingPhase 3NCT07495852
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Sponsor
Glaukos Corporation
Enrollment
510 participants
Start Date
Feb 17, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye
Exclusion Criteria3
- Prior incisional glaucoma surgery in the study eye
- Prior argon laser trabeculoplasty (ALT) in the study eye
- Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGGen 2 Travoprost Intracameral Implant
Travoprost
DRUGTimolol eye drops 0.5%
Timolol 0.5%
PROCEDURESham Procedure
Sham implant administration
OTHERplacebo eye drops
Artificial Tears
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07495852
Related Trials
Glaucoma Related Quality of Life
NCT075100871 location
Efficacy and Safety of the ELIOS Laser in Combined Cataract and Glaucoma Surgery
NCT067601691 location
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
NCT0716890214 locations
A Trial of Hydrus Microstent Versus Goniotomy
NCT062894911 location
Advancing Pediatric Retinal Imaging With Auto-aligned OCT
NCT068415751 location